Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Gilead goes long-acting in HIV
Sunlenca gets a US green light at the second time of asking, but combination success will be vital to it fulfilling its promise.
An expensive new haemophilia gene therapy hits the US
The approval is good for CSL, and better for Uniqure.
If at first... pharma’s most drawn-out development timelines revealed
Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.
